|
|
|
Volumn 271, Issue 7267, 2003, Pages 364-
|
|
The EU clinical trials directive could spell the end of UK R&D activity
a
a
ADAllen Pharma
*
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
DRUG;
PLACEBO;
BIOTECHNOLOGY;
CLINICAL TRIAL;
DRUG INDUSTRY;
DRUG MARKETING;
DRUG RESEARCH;
DRUG SAFETY;
EUROPEAN UNION;
FOOD AND DRUG ADMINISTRATION;
FORGERY;
GOOD CLINICAL PRACTICE;
GOOD MANUFACTURING PRACTICE;
GOVERNMENT;
HUMAN;
INFORMATION PROCESSING;
MEDICAL ETHICS;
NOTE;
PATIENT RIGHT;
PHASE 1 CLINICAL TRIAL;
PRACTICE GUIDELINE;
QUALITY CONTROL;
RISK ASSESSMENT;
UNITED KINGDOM;
UNITED STATES;
|
|
EID: 0141617485
PISSN: 00316873
EISSN: None
Source Type: Journal
DOI: None Document Type: Note |
|
Times cited : (3)
|
|
References (0)
|